SecBot SecBot
Institutional Cluster

AMLX

Amylyx Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed2mo ago
Institutional cluster: 11 buyers, 2 sellers (bullish)
Actionable Insight ▲ Bullish

The institutional cluster signals conviction ahead of the avexitide Phase 3 readout, but the 45-day reporting lag means these positions were taken at Q2-end prices (~$18) versus the current ~$24. Traders should watch for any insider buying or pre-readout positioning updates. The divergent insider signal (only $51K bought) suggests caution — the cluster's thesis may already be priced in. Key risk: if LUCIDITY misses, the stock could gap down sharply given the pre-revenue profile.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+20d
AMLX ▲ +54.69% at T+20d
LONG call ✓ call won +54.69% · α vs SPY +56.67% · entry $21.43 → $33.15
Next anchor: T+60d in 13d
Latest observation: T+48 +7.99% FF3 residual α
Entry = T+0 close
Aug 15, 2026
via day close
T+1d
+63.84%
call +63.84% · α +64.51%
$35.11
settled 2mo ago
T+5d
+78.02%
call +78.02% · α +79.21%
$38.15
settled 2mo ago
T+20d
+54.69%
call +54.69% · α +56.67%
$33.15
settled 6w ago
T+60d
Pending
in 13d

Executive Summary

A strong institutional cluster formed in AMLX during Q2 2026, with 11 buyers accumulating a net $76.7M in new positions versus only 2 sellers trimming $7.9M. The buying was dominated by major passive and active managers, including JPMorgan (doubling to $34.9M) and Morgan Stanley (adding to $56.2M), alongside a new $13.2M stake from Aberdeen Group. This cluster follows the company's Q2 earnings miss and pre-revenue cash burn, but likely reflects positioning ahead of the pivotal Phase 3 LUCIDITY data readout for avexitide in post-bariatric hypoglycemia, expected in late August/early September 2026.

Key Financial Metrics

Direction
accumulating
Buy Value
$111.4M
Sell Value
$7.9M
Net Flow
$68.8M

Institutional Positions

Net institutional flow: $68.8M

▲ Buyers (11)

InstitutionActionChangePosition ValueValue Δ
JPMorganDOUBLED+1067.2%$34.9M$32.9M
Morgan StanleyADD+43.9%$56.2M$26.0M
Aberdeen GroupNEW—$13.2M$13.2M
Walleye CapitalDOUBLED+202.4%$3.4M$2.5M
Russell Investments GroupADD+47.6%$1.6M$748.0K

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Deutsche BankTRIM-56%$17.6M-$7.6M
Zurcher Kantonalbank (Zurich Cantonalbank)TRIM-58.4%$567.0K-$262.5K

Key Facts

  • 11 institutional buyers vs 2 sellers in Q2 2026
  • Net institutional accumulation of $76.7M across 11 buyers
  • JPMorgan doubled its position to $34.9M (+1067% shares)
  • Morgan Stanley added to $56.2M (+43.9% shares)
  • Aberdeen Group initiated a new $13.2M position
  • Deutsche Bank trimmed $7.6M (-56% of its stake)
  • Cluster formed after Q2 2026 earnings miss (net loss $43.4M, EPS -$0.39 vs -$0.36 consensus)
  • Key catalyst: Phase 3 LUCIDITY topline data for avexitide expected late Aug/early Sep 2026
  • Insider buying was minimal ($51K from 1 open-market buyer), showing divergent insider vs institutional signals

Financial Impact

11 institutions accumulated $111.4M in total holdings (net change +$76.7M) while 2 sellers reduced by $7.9M, for a net institutional inflow of approximately $68.8M

institutional ownershipfloat turnover

Risk Factors

  • Phase 3 LUCIDITY data miss would be catastrophic for a pre-revenue biotech
  • 45-day 13F reporting lag means positions may already be unwound
  • Insider buying was minimal ($51K), showing lack of C-suite conviction
  • Cash burn continues ($250.8M remaining, runway into 2028)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-AMLX-2026-Q2
10 reports for AMLX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AMLX — sortable, filterable
TypeNow
Oct 5, 2026
21d ago
144
NEUTRAL ★ 3/10
$28.04awaiting T+20——
Sep 14, 2026
6w ago
Insider Cluster
MIXED ★ 4/10
$33.15 $26.85▼ −19.00%▼ −21.73%—
Sep 11, 2026
6w ago
144
NEUTRAL ★ 2/10
$33.64 $27.48▼ −18.31%▼ −20.57%—
Aug 18, 2026
9w ago
8-K
BULLISH ★ 7/10
$35.11 $33.05▼ −5.87%▼ −4.88%—
Aug 15, 2026
10w ago
Institutional Cluster
BULLISH ★ 6/10
$21.43 $33.15▲ +54.69%▲ +56.67%—
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 5/10
$24.19 $33.96▲ +40.39%▲ +39.79%—
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 3/10
$13.91 $18.38▲ +32.14%▲ +30.24%—
Apr 23, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$17.32 $13.61▼ −21.42%▼ −26.05%—
Mar 2, 2026
34w ago
Insider Cluster
NEUTRAL ★ 3/10
$15.30 $12.76▼ −16.60%▼ −8.66%—
Feb 23, 2026
35w ago
Insider Cluster
BEARISH ★ 7/10
$13.90 $13.53▲ +2.66%▼ −1.28%—
Showing 10 of 10

US Market Status

Market Closed — Opens Wed (11h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 15, 2026